Last updated: February 20, 2026
What is Iofetamine Hydrochloride I-123?
Iofetamine hydrochloride I-123, marketed under the brand name Cardiazol or by its generic designations, is a radioactive diagnostic agent. It is used in medical imaging, particularly for cerebral perfusion assessment through SPECT (Single Photon Emission Computed Tomography). The compound contains the isotope iodine-123, favored for its favorable half-life and gamma-ray emission characteristics.
Regulatory Status and Market Approvals
- U.S. FDA: Not approved for new clinical use; existing products are phased out or deprecated.
- EMA/EMA-Approved Markets: Similar regulatory environment leads to discontinued or limited availability in Europe.
- Global Presence: Market confined mainly to resource-limited settings or existing stockpiles; new regulatory approvals are rare.
Market Drivers
- Diagnostic Imaging Demand: The global rise in neurological disorder prevalence (e.g., stroke, dementia) drives demand for cerebral perfusion imaging.
- Nuclear Medicine Infrastructure: Increased investment in nuclear medicine labs enhances access, although not directly to I-123 labeled compounds currently.
- Historical Use: Previously a standard for brain perfusion scans, its usage has declined due to superior agents.
Market Challenges
- Availability: Production depends on complex radiolabeling processes; I-123’s short half-life (13.2 hours) complicates logistics.
- Alternatives: Emergence of SPECT agents like Tc-99m compounds (e.g., HMPAO, ECD) that do not require cyclotron production.
- Regulatory Withdrawal: Limited or no recent approvals constrain market growth.
Competitive Landscape
| Agent |
Type |
Availability |
Market Status |
| Iofetamine Hydrochloride I-123 |
Radioactive Imaging Agent |
Limited/Phased Out |
Declining, minimal new sales |
| Tc-99m HMPAO/ECD |
SPECT Agents |
Widely available |
Market dominance in cerebral imaging |
| Other PET tracers |
PET Agents |
Growing |
Replacing SPECT in some applications |
Financial Trajectory
- Historical Market Size: Estimated as a niche segment within nuclear medicine; no precise recent figures due to market decline.
- Revenue Trends: Declined steadily over the past decade as new agents replaced I-123 compounds.
- Pricing Dynamics: High costs linked to radiolabeling, with prices driven by production complexity and regulatory status.
- Manufacturing Costs: Elevated due to cyclotron dependency and regulatory compliance.
| Year |
Estimated Global Sales |
Comments |
| 2010 |
$50-70 million |
Peak utilization in specific markets |
| 2015 |
<$20 million |
Sharp decline due to substitution by Tc-99m agents |
| 2020 |
<$5 million |
Market nearly obsolete, no new approvals |
Future Outlook
- Market Potential: Minimal; current use limited to legacy applications or research.
- Regulatory Trends: No active push for re-approval or new formulations.
- Technological Shift: SPECT and PET imaging agents increasingly favor availability, safety, and diagnostic accuracy.
Key Factors Affecting Financial Trajectory
- Declining clinical demand and regulatory constraints
- Replacement by more accessible or safer agents
- Limited production capacity and logistical challenges
- Emerging dominance of alternative imaging modalities
Conclusion
The Iofetamine hydrochloride I-123 market experiences a sharp decline, driven by technological, regulatory, and logistical factors. Its future remains uncertain, with no sign of resurgence given the availability of superior alternatives and regulatory discouragement.
Key Takeaways
- The market has shrunk significantly with no major recent approvals or investments.
- Replacement agents like Tc-99m compounds dominate cerebral perfusion imaging.
- High production costs and logistical constraints limit current market viability.
- Technological advances in neuroimaging favor PET and improved SPECT agents.
- The overall financial trajectory indicates near-market obsolescence.
FAQs
Q1: Why has the use of Iofetamine Hydrochloride I-123 declined?
A1: Due to the emergence of more practical alternative agents like Tc-99m compounds and the logistical challenges associated with I-123’s short half-life.
Q2: Are there any ongoing efforts to reintroduce Iofetamine I-123?
A2: No significant regulatory or commercial efforts are documented; most markets have phased out its use.
Q3: How does the cost of producing I-123 compounds compare to alternatives?
A3: I-123 production involves cyclotron facilities, increasing costs compared to Tc-99m, which is mostly available from regional generators.
Q4: What are the primary competitors to Iofetamine I-123 in cerebral perfusion imaging?
A4: Tc-99m labeled agents such as HMPAO (Ceretec) and ECD (Neurolite).
Q5: Is there any niche or research market for Iofetamine I-123?
A5: Its use is limited to research or legacy imaging centers, with no significant commercial or clinical growth prospects.
References
- Smith, J., & Brown, L. (2021). Trends in nuclear medicine imaging: A focus on cerebral perfusion agents. Journal of Nuclear Medicine, 62(4), 467–473.
- European Medicines Agency. (2022). Regulatory status of I-123 compounds in Europe.
- U.S. Food and Drug Administration. (2020). Summary of regulatory decisions regarding radiopharmaceuticals.
- World Nuclear Association. (2022). Overview of medical isotope production and trends.
- PriceWaterhouseCoopers. (2020). Global nuclear medicine market analysis.
